IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Swiss National Bank

Key Points

• The Swiss National Bank reduced its holdings in IQVIA Holdings Inc. by 0.6%, selling 3,100 shares and now owning a total of 511,880 shares worth approximately $90,244,000.
• Insider trading activity included sales by Keriann Cherofsky and Eric Sherbet, with Cherofsky selling 549 shares and Sherbet disposing of 5,800 shares, reflecting a decrease in their ownership positions.
• IQVIA recently reported earnings of $2.81 EPS for the quarter, beating estimates, with revenue rising 5.3% year-over-year to $4.02 billion.

Swiss National Bank reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 0.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 511,880 shares of the medical research company's stock after selling 3,100 shares during the period. Swiss National Bank owned 0.30% of IQVIA worth $90,244,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. American National Bank & Trust purchased a new stake in IQVIA during the first quarter valued at about $26,000. Golden State Wealth Management LLC raised its position in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC bought a new stake in IQVIA in the 1st quarter valued at $33,000. ST Germain D J Co. Inc. grew its stake in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. purchased a new position in shares of IQVIA during the 4th quarter worth about $39,000. 89.62% of the stock is owned by institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Redburn Partners set a $188.00 price target on shares of IQVIA in a report on Friday, May 23rd. UBS Group increased their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Truist Financial increased their price objective on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Cowen reiterated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Seven analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Trading Up 3.3%

IQVIA stock traded up $6.03 during mid-day trading on Tuesday, hitting $186.12. The stock had a trading volume of 1,487,624 shares, compared to its average volume of 2,371,880. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The stock has a market capitalization of $31.64 billion, a PE ratio of 26.93, a P/E/G ratio of 1.98 and a beta of 1.30. The stock has a 50-day simple moving average of $167.92 and a two-hundred day simple moving average of $168.89.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.64 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.